|1.||Gong, Xiao-Yuan: 1 article (04/2015)|
|2.||Gu, Run-Xia: 1 article (04/2015)|
|3.||Zhou, Chun-Lin: 1 article (04/2015)|
|4.||Wang, Jian-Xiang: 1 article (04/2015)|
|5.||Li, Yan: 1 article (04/2015)|
|6.||Zhao, Xing-Li: 1 article (04/2015)|
|7.||Wei, Shu-Ning: 1 article (04/2015)|
|8.||Wang, Ying: 1 article (04/2015)|
|9.||Cao, Zeng: 1 article (04/2015)|
|10.||Wei, Hui: 1 article (04/2015)|
02/01/2015 - "Between 2005 and 2012, we analyzed 191 HSCT in adult patients with leukemia with reduced-intensity conditioning (RIC) regimen (n = 79) and with myeloablative conditioning (MAC) regimen (n = 112). "
04/01/2014 - "We report outcomes after single (s) and double (d) umbilical cord blood transplantation (UCBT) after myeloablative conditioning (MAC) regimen for 239 patients transplanted for acute leukemia in first complete remission (CR1). "
|2.||Immune Reconstitution Inflammatory Syndrome
|4.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
12/01/2014 - "Based on these results, we suggest that (1) class 3 HR thalassemia patients can safely receive HSCT with our novel RTC regimen and achieve the same excellent outcome as low/standard-risk thalassemia patients who received the standard MAC regimen, and further, (2) that this novel RTC approach should be tested in the low/standard-risk patient population. "
|1.||Transplantation (Transplant Recipients)
|2.||Highly Active Antiretroviral Therapy (HAART)